Dean Papaliodis, MD
Sports Medicine · Fort Worth, TXNPI 1194041558
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Depuy Synthes Products, Inc. at 40.7% of the total. Reporting peaked in 2021 at $12,217 and has fallen 87.9% since, to $1,480 in 2025.
Across 228 payments — averaging $163.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Depuy Synthes Products, Inc.$15K
- Pylant Medical$7K
- Encore Medical, LP$4K
- Stryker$3K
- Arthrex$3K
- Medical Device Business Services, Inc.$1K
- plus $4K from 18 others
What the payments were for
- Consulting fees$15,14041%
- Travel & lodging$8,83924%
- Food & beverage$7,51020%
- Education$5,75915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Depuy Synthes Products, Inc. | 6 | $15,176 |
| Pylant Medical | 23 | $6,956 |
| Encore Medical, LP | 19 | $4,032 |
| Stryker | 29 | $3,123 |
| Arthrex | 41 | $3,047 |
| Medical Device Business Services, Inc. | 9 | $1,142 |
| Zimmer Biomet | 12 | $852 |
| Pacira Pharmaceuticals Incorporated | 10 | $604 |
| Johnson & Johnson | 19 | $512 |
| Pacira Therapeutics, Inc. | 32 | $436 |
| Abanza Inc. | 3 | $295 |
| Smith+Nephew | 3 | $249 |
| Embody, Inc. | 2 | $244 |
| Bioventus LLC | 5 | $144 |
| Biotissue Holdings Inc. | 1 | $100 |
| Davol Inc. | 2 | $69 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| Orthofix Medical, Inc. | 3 | $51 |
| Acumed LLC | 1 | $50 |
| Amgen | 1 | $29 |
| Vertex | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Boston Scientific | 1 | $15 |
| Sanara Medtech Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VAPR$8,972
- FMS$6,444
- DJO Surgical Empowr Knee System$1,337
- DJO Surgical TaperFill Hip System$1,337
- HIP ARTHROSCOPY ACCESS & INSTRUMENTATION SET$1,187
- DJO Surgical Cobalt HV Bone Cement$1,003
- Actishield$781
- DJO Surgical 3DKnee System$771
- DJO SURGICAL$670
- DJO Surgical Exprt Revision Hip$645
- VISUALIZATION$484
- IOVERA SYSTEM$335
- WasherCap Fixation System 10mm$254
- Kischner wire$254
- HEALIX KNOTLESS PEEK$253
- VARIAX$173
- Accelero-None$148
- Bone Anchors with Arthroscopic Delivery System$147
- Oxford$141
- ICONIX$141
How this compares
$37,248 in reported general payments places this provider in the 85th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZilrettaTriamcinolone Acetonide | 11 | $10,616 |
| Celecoxib | 33 | $687 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $504 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $490 |
| Methocarbamol | 31 | $260 |
| Methylprednisolone | 21 | $139 |
| Cephalexin | 20 | $56 |
| Diclofenac Sodium | 21 | $48 |
| Gabapentin | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pacira Pharmaceuticals IncorporatedZilretta | $604 | $10,61611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 437 sports medicine providers in Texas.
Other sports medicine in Fort Worth
- Thomas DeberardinoSan Antonio$3.5M
- Robert ScheinbergDallas$2.2M
- Walter LoweHouston$1.4M
- Reed BartzSunnyvale$1.2M
- James GregoryHouston$565K
- John McDonaldAustin$499K
- James McKinleyTyler$305K
- Kelechi OkorohaDallas$297K
- Leon PaulosPearland$289K
- Marc LabbeThe Woodlands$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.